Eli Lilly has received the approval for the Abnehmspritze Mounjaro in China

(Image: railwayfx – AdobeStock)

The first in China was launched in July 2023 by the Chinese pharmaceutical industry of Benemae Pharmaceutical into the war. In June 2024, the approval for Semaglutide/Wegovy from Novo Nordisk followed. With the approval for his Preparation Mounjaro has put Nun and Eli Lilly Zugang on the Chinese Wachstumsmarkt.

The device is used by the first Wirkstoff with dual Wirkmechanism in the Glucagon-ähnliches-Peptid-1 (GLP-1)-Rezeptoragonists. Sasmitha Sahu, Pharma-Analyst des Analyse- und Beratungsunternehmens Globaldata, erklärt: “Die Zulassung von Eli Lillys Tirzepatid in China kommt zur richtigen Zeit, angesichts der eigenden Adipositasraten. The dual mechanism of action of the hormone GLP-1 and GIP was potentially weight craving and blutzucker control.”

The analysts have earned more than 45 million. Adiposity Fälle in China before 2024. The National People’s Republic of China launched a three-year camp “Year of Weight Management” in June 2024 in the form of a “Gesundes China” initiative (2019-2030) and the implementation plans for the prevention and control of Adiposity in Children and Jugendlichen. “These additional follow-up studies of adiposity medicines under the Chinese influence are important for innovative treatment options,” Sahu said.

Semaglutid patent ends in China früher

Global Recommendations of Adiposity Therapies for Lieferproblemen. Chinese pharmaceutical companies are prepared for this situation and reimburse their own GLP-1 biosimilars. In July 2023, Huadong Medicine’s biosimilar in China for the new Nordisks is a subcutaneous GLP-1 agonist liraglutide for the treatment of obesity; There are more biosimilars available in the pipeline. Eight Semaglutid biosimilars have appeared on the market in China after the expiration of the Semaglutid patents in 2026 in China before the global approval until 2031. The US patent for the first time in 2036, without biosimilars being available, even in China.